Loading grant details…
Deciphering inv3/t(3;3) Myeloid Leukemia Vulnerabilities via Proteogenomics and N-terminal Proteomics
| Funder | NATIONAL CANCER INSTITUTE |
|---|---|
| Recipient Organization | University of California Los Angeles |
| Country | United States |
| Start Date | Aug 01, 2024 |
| End Date | Jul 31, 2027 |
| Duration | 1,094 days |
| Number of Grantees | 1 |
| Roles | Principal Investigator |
| Data Source | NIH (US) |
| Grant ID | 10997848 |
Grant Description
PROJECT SUMMARY The overall objective of this proposal is to develop and apply novel proteogenomic approaches to identify therapeutic vulnerabilities of chromosome 3 rearranged myeloid leukemias. Chromosome 3 inversions or transversions (inv3/t(3;3)) leukemias result in aberrant overexpression of oncogenic transcription factor MECOM
(MDS1 and EVI1 complex locus, specifically a truncated isoform EVI1) and decreased expression of tumor suppressor GATA2. Inv3/t(3;3) abnormal myeloid leukemia patients have no targeted precision therapies as they are resistant to standard of care regimens like Tyrosine Kinase Inhibitors (TKIs), and so experience dismal 5-
year survival rates of
All Grantees
University of California Los Angeles
Interested in applying for this grant?
Complete our application form to express your interest and we'll guide you through the process.
Apply for This GrantQuick Summary
Related Grants
